Recurrent Uncomplicated Urinary Tract Infections – The Place of Immuno-prophylaxis
1. Foxman B, Epidemiology of urinary tract infections: incidence, morbidity, and economic costs, Am J Med, 2002;113(Suppl. 1A):5S–13S.
2. Leibovici L, Alpert G, Laor A, et al., Urinary tract infections and sexual activity in young women, Arch Intern Med, 1987;147:345–7.
3. Nicolle LE, Harding GK, Preiksaitis J, et al., The association of urinary tract infection with sexual intercourse, J Infect Dis, 1982;146:579–83.
4. Foxman B, Barlow R, D'Arcy H, et al., Urinary tract infection: self-reported incidence and associated costs, Ann Epidemiol, 2000;10:509–15.
5. Schappert SM, Ambulatory care visits of physician offices, hospital outpatient departments, and emergency departments: United States, 1995, Vital Health Stat 13, 1997;1–38.
6. Naber KG, Schito G, Botto H, et al., Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy, Eur Urol, 2008;54:1164–75.
7. Farrell DJ, Morrissey I, De Rubeis D, et al., A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection, J Infect, 2003;46:94–100.
8. Ho PL, Yip KS, Chow KH, et al., Antimicrobial resistance among uropathogens that cause acute uncomplicated cystitis in women in Hong Kong: a prospective multicenter study in 2006 to 2008, Diagn Microbiol Infect Dis, 2010;66:87–93.
9. Kahlmeter G, Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The
ECO.SENS study, Int J Antimicrob Agents, 2003;22 (Suppl. 2):49–52.
10. Raz R, Chazan B, Kennes Y, et al., Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX- resistant uropathogens, Clin Infect Dis, 2002;34:1165–9.
11. Grabe M, Bjerklund-Johansen TE, Botto H, et al., European Association of Urology. Guidelines on Urological Infections, 2010. Available at:
www.uroweb.org/gls/pdf/Urological%20 Infections%202010.pdf (accessed 15 June 2011).
12. Lichtenberger P, Hooton TM, Complicated urinary tract infections, Curr Infect Dis Rep, 2008;10:499-504.
13. Afssaps, Agence Française de Sécurité Sanitaire des Produits de Santé Lettre aux professionnels de santé: Nitrofurantoïne et risque de survenue d’effets indésirables hépatiques et pulmonaires lors de traitements prolongés 2011. Available at:
www.afssaps.fr/Infos-de-securite/Lettres-aux-professionnels- de-sante/Nitrofurantoine-et-risque-de-survenue-d-effets- indesirables-hepatiques-et-pulmonaires-lors-de-traitements- prolonges-Lettre-aux-professionnels-de-sante (accessed: 26 May 2011).
14. Borchert D, Sheridan L, Papatsoris A, et al., Prevention and
treatment of urinary tract infection with probiotics: Review and research perspective, Indian J Urol, 2008;24:139–44.
15. Borriello SP, Hammes WP, Holzapfel W, et al., Safety of probiotics that contain lactobacilli or bifidobacteria, Clin Infect Dis, 2003;36:775–80.
16. Cadieux PA, Burton J, Devillard E, et al., Lactobacillus by- products inhibit the growth and virulence of uropathogenic, Escherichia coli, J Physiol Pharmacol, 2009;60(Suppl. 6):13–8.
17. Stapleton AE, Au-Yeung M, Hooton TM, et al., Randomized, Placebo-Controlled Phase 2 Trial of a Lactobacillus crispatus Probiotic Given Intravaginally for Prevention of Recurrent Urinary Tract Infection, Clin Infect Dis, 2011;52:1212–7.
18. Sunden F, Hakansson L, Ljunggren E, et al., Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying, J Urol, 2010;184:179–85.
19. Raz R, Stamm WE, A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections, N Engl J Med, 1993;329:753–6.
20. Jepson RG, Craig JC, Cranberries for preventing urinary tract infections, Cochrane Database Syst Rev, 2008;CD001321.
21. Ferrara P, Romaniello L, Vitelli O, et al., Cranberry juice for the prevention of recurrent urinary tract infections: a randomized controlled trial in children, Scand J Urol Nephrol, 2009;43:369–72.
22. Barbosa-Cesnik C, Brown MB, Buxton M, et al., Cranberry juice fails to prevent recurrent urinary tract infection: results from a randomized placebo-controlled trial, Clin Infect Dis, 2011;52:23–30.
23. Botto H, Neuzillet Y, Effectiveness of a cranberry (Vaccinium macrocarpon) preparation in reducing asymptomatic bacteriuria in patients with an ileal enterocystoplasty, Scand J Urol Nephrol, 2010;44:165–8.
24. Naber KG, Cho YH, Matsumoto T, et al., Immunoactive prophylaxis of recurrent urinary tract infections: a meta- analysis, Int J Antimicrob Agents, 2009;33:111–9.
25. Bessler WG, vor dem Esche U, Zgaga-Griesz A, et al., Immunostimulatory properties of the bacterial extract OM-89 in vitro and in vivo, Arzneimittelforschung, 2010;60:324–9.
26. Bauer HW, Alloussi S, Egger G, et al., A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections, Eur Urol, 2005;47:542–8, discussion 8.
27. Magasi P, Panovics J, Illes A, et al., Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial, Eur Urol, 1994;26:137–40.
28. Schulman CC, Corbusier A, Michiels H, et al., Oral immunotherapy of recurrent urinary tract infections: a double-blind placebo-controlled multicenter study, J Urol, 1993;150:917–21.
29. Svanborg C, Bergsten G, Fischer H, et al., Uropathogenic Escherichia coli as a model of host-parasite interaction,
Curr Opin Microbiol, 2006;9:33–9.
30. Cerutti A, Chen K, Chorny A, Immunoglobulin responses at the mucosal interface, Annu Rev Immunol, 2011;29:273–93.
31. Nielubowicz GR, Mobley HL, Host-pathogen interactions in urinary tract infection, Nat Rev Urol, 2010;7:430–41.
32. Song J, Abraham SN, TLR-mediated immune responses in the urinary tract, Curr Opin Microbiol, 2008;11:66–73.
33. Hawn TR, Scholes D, Li SS, et al., Toll-like receptor polymorphisms and susceptibility to urinary tract infections in adult women, PLoS One, 2009;4:e5990.
34. Hawn TR, Scholes D, Wang H, et al., Genetic variation of the human urinary tract innate immune response and asymptomatic bacteriuria in women, PLoS One, 2009;4:e8300.
35. Ragnarsdottir B, Jonsson K, Urbano A, et al., Toll-like receptor 4 promoter polymorphisms: common TLR4 variants may protect against severe urinary tract infection, PLoS One, 2010;5:e10734.
36. Bessler WG, Puce K, vor dem Esche U, et al., Immunomodulating effects of OM-89, a bacterial extract from Escherichia coli, in murine and human leukocytes, Arzneimittelforschung, 2009;59:571–7.
37. Chiavaroli C, Moore A, An hypothesis to link the opposing immunological effects induced by the bacterial lysate OM-89 in urinary tract infection and rheumatoid arthritis, BioDrugs, 2006;20:141–9.
38. Van Pham T, Kreis B, Corradin-Betz S, et al., Metabolic and functional stimulation of lymphocytes and macrophages by an Escherichia coli extract (OM-89): in vitro studies, J Biol Response Mod, 1990;9:231–40.
39. Schmidhammer S, Ramoner R, Holtl L, et al., An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells, Urology, 2002;60:521–6.
40. Marchant A, Duchow J, Goldman M, Adhesion molecules in antibacterial defenses: effects of bacterial extracts, Respiration, 1992;59(Suppl. 3):24–7.
41. Huber M, Krauter K, Winkelmann G, et al., Immunostimulation by bacterial components: II. Efficacy studies and meta- analysis of the bacterial extract OM-89, Int J Immunopharmacol, 2000;22:1103–11.
42. Huber M, Baier W, Serr A, et al., Immunogenicity of an E. coli extract after oral or intraperitoneal administration: induction of antibodies against pathogenic bacterial strains, Int J Immunopharmacol, 2000;22:57–68.
43. Czerwionka-Szaflarska M, Pawlowska M, Influence of Uro-Vaxom on sIgA level in urine in children with recurrent urinary tract infections, Arch Immunol Ther Exp (Warsz), 1996;44:195–7.
44. Frey C, Obolensky W, Wyss H, Treatment of recurrent urinary tract infections: efficacy of an orally administered biological response modifier, Urol Int, 1986;41:444–6.
45. Tammen H, Immunobiotherapy with Uro-Vaxom in recurrent urinary tract infection. The German Urinary Tract Infection Study Group, Br J Urol, 1990;65:6–9.
EUROPEAN UROLOGICAL REVIEW
119
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76